Skip to main content
GNLX
NASDAQ Life Sciences

Genelux Q3 Loss Widens to $10.3M; Going Concern Reaffirmed, Runway Into Q1 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.88
Mkt Cap
$86.871M
52W Low
$1.77
52W High
$5.89
52W Position info
6.2% above low
Off High info
68% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

GNLX is trading near its 52-week low of $1.77 (6.2% above the low).

Summary

Genelux's Q3 loss widened to $10.3 million on higher Phase 3 costs, and with $15.5 million pro forma liquidity the going concern warning stands with runway only into Q1 2027.


Key Events · Earnings and Guidance · GNLX

  • Q3 Loss Widens on Phase 3 Costs

    Net loss was $10.285 million ($0.23 per share) versus $7.950 million a year earlier, above the $8.78 million consensus; R&D rose to $6.909 million from $4.741 million on the Phase 3 On Prime/GOG-3076 trial.

  • Going Concern and Q1 2027 Runway

    The company reaffirmed substantial doubt about its ability to continue as a going concern, with $10.4 million of cash, equivalents, restricted cash and marketable securities at September 30, 2026 expected to fund operations only into the first quarter of 2027.

  • ATM Sales Fund the Gap

    135,000 shares were sold for $0.4 million net in Q3, and 2,552,458 shares for $5.1 million net in October-November 2026, bringing pro forma liquidity to $15.5 million.

  • Cash Burn of $18.4 Million

    Operating activities used $18.429 million in the first nine months of 2026, against a $28.685 million net loss, with stock-based compensation of $6.990 million as the main non-cash add-back.


Analysis · GNLX · Life Sciences

The going concern warning is not boilerplate: Genelux burned $18.4 million of cash in the first nine months of 2026 and ended September with $10.4 million of cash and securities, leaving roughly one quarter of funding without new capital. The Q3 loss of $10.3 million ($0.23 per share) came in above the $8.78 million consensus as Phase 3 On Prime/GOG-3076 trial costs pushed R&D to $6.9 million from $4.7 million a year ago. Management has been plugging the gap with the TD Securities ATM: 135,000 shares for $0.4 million in Q3 and another 2,552,458 shares for $5.1 million net in October-November, lifting pro forma liquidity to $15.5 million. That buys time into Q1 2027 but not through the trial, so another raise — and more dilution — is the base case.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GNLX was trading at $1.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $86.9M. The 52-week trading range was $1.77 to $5.89. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GNLX - Latest Insights

GNLX
Nov 16, 2026, 4:23 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.88
Real-time Price: $1.89 info
Change: +$0.010 (+0.53%) info
Market Cap: $86.871M info
GNLX
Sep 09, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.52
Real-time Price: $1.89 info
Change: -$0.630 (-25%) info
Market Cap: $86.871M info
GNLX
Aug 13, 2026, 4:20 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.63
Real-time Price: $1.89 info
Change: -$0.740 (-28%) info
Market Cap: $86.871M info
GNLX
Aug 13, 2026, 1:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.75
Real-time Price: $1.89 info
Change: -$0.860 (-31%) info
Market Cap: $86.871M info
GNLX
May 07, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.83
Real-time Price: $1.89 info
Change: -$0.940 (-33%) info
Market Cap: $86.871M info